A heterozygous effect for PINK1 mutations in Parkinson's disease?

Objective To investigate the significance of PINK1 mutations in sporadic Parkinson's disease (PD). Methods We determined the frequency of PINK1 mutations by direct sequencing in a large series of PD patients with apparently sporadic disease (n = 768). Results Twelve heterozygous mutations were...

Full description

Saved in:
Bibliographic Details
Published inAnnals of neurology Vol. 60; no. 4; pp. 414 - 419
Main Authors Abou-Sleiman, Patrick M., Muqit, Miratul M. K., McDonald, Neil Q., Yang, Yan Xiang, Gandhi, Sonia, Healy, Daniel G., Harvey, Kirsten, Harvey, Robert J., Deas, Emma, Bhatia, Kailash, Quinn, Niall, Lees, Andrew, Latchman, David S., Wood, Nicholas W.
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.10.2006
Willey-Liss
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective To investigate the significance of PINK1 mutations in sporadic Parkinson's disease (PD). Methods We determined the frequency of PINK1 mutations by direct sequencing in a large series of PD patients with apparently sporadic disease (n = 768). Results Twelve heterozygous mutations were identified, nine in PD patients and three in control subjects. Interpretation Given the difficulty in interpreting the pathogenic significance of the heterozygous mutations that have already been reported in parkin and DJ‐1, we first determined the frequency of heterozygous PINK1 mutations in the general population by sequencing a large number of control subjects (n = 768), then subsequently assessed their functional significance by examining their effects on stress‐induced alterations to the mitochondrial membrane potential (ΔΨm). We demonstrate an enrichment of heterozygous mutations in sporadic PD patients compared with matched control subjects (1.2% in PD vs 0.4% in control subjects). Furthermore, we show that they adversely affect ΔΨm in a similar way to the familial G309D mutation. Although it remains difficult to conclusively demonstrate the pathogenicity of heterozygous mutations, the results of this study and the previously reported subclinical nigrostriatal dysfunction in carriers of heterozygous PINK1 mutations suggest the possibility that these heterozygous mutations are a significant risk factor in the development of later onset PD. Ann Neurol 2006
Bibliography:Parkinson's Disease Society, United Kingdom
Medical Research Council (MRC) program - No. G0400000
Medical Research Council Clinical Research Training Fellowship
ark:/67375/WNG-287X9187-N
Brain Research Trust
istex:6CE7C459FEF8A961BD4D38267460919D919D227F
ArticleID:ANA20960
Wellcome Trust Research Training Fellowship
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0364-5134
1531-8249
DOI:10.1002/ana.20960